Sarah McLeod, PhD, breaks down high cure rates with zoliflodacin for uncomplicated gonorrhea

New subgroup analyses from the global phase 3 zoliflodacin trial highlight the drug’s efficacy against multidrug-resistant Neisseria gonorrhoeae, including ciprofloxacin-resistant strains, across all infection sites and patient subgroups. The data were presented at IDWeek 2025 in Atlanta, Georgia.